BOSTON, Feb. 25, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 10, 2016, to discuss financial results of the fourth quarter and year ended December 31, 2015. The call details are as follows:
The teleconference replay will be available at approximately one hour after completion through Wednesday, March 16, 2016, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10081480.
The archived webcast will be available for one year via the aforementioned URLs.
About Juniper Pharmaceuticals Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage novel intra-vaginal drug delivery technologies. Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.
Contact Amy Raskopf Director, Corporate Communications, Juniper Pharmaceuticals, Inc. (917) 673-5775 / email@example.com
To receive Juniper's press releases, SEC filings or calendar alerts by email click here.
Follow us on LinkedIn
SOURCE Juniper Pharmaceuticals, Inc.